Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF

AIMS: Chronic obstructive pulmonary disease (COPD) is an important comorbidity in heart failure (HF) with reduced ejection fraction (HFrEF), associated with worse outcomes and often suboptimal treatment because of under‐prescription of beta‐blockers. Consequently, additional effective therapies are...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Heart Fail
Main Authors: Dewan, Pooja, Docherty, Kieran F., Bengtsson, Olof, de Boer, Rudolf A., Desai, Akshay S., Drozdz, Jaroslaw, Hawkins, Nathaniel M., Inzucchi, Silvio E., Kitakaze, Masafumi, Køber, Lars, Kosiborod, Mikail N., Langkilde, Anna Maria, Lindholm, Daniel, Martinez, Felipe A., Merkely, Béla, Petrie, Mark C., Ponikowski, Piotr, Sabatine, Marc S., Schou, Morten, Sjöstrand, Mikaela, Solomon, Scott D., Verma, Subodh, Jhund, Pardeep S., McMurray, John J.V.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Ltd. 2021
Assuntos:
Clinical Trials: Dapa‐hf
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8247863/
https://ncbi.nlm.nih.gov/pubmed/33368858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejhf.2083
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados